# Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

> **NCT01353404** · PHASE1 · COMPLETED · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 24 (actual)

## Conditions studied

- Hyperlipidemia

## Interventions

- **DRUG:** Sequence 1
- **DRUG:** Sequence 2
- **DRUG:** Seqeunce 3
- **DRUG:** Sequence 4
- **DRUG:** Sequence 5
- **DRUG:** Sequence 6

## Key facts

- **NCT ID:** NCT01353404
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-08
- **Final completion:** 2011-08
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2012-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353404, "Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01353404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*